OptiNose (OPTN) and Albany Molecular Research (AMRI) Head to Head Comparison

OptiNose (NASDAQ: OPTN) and Albany Molecular Research (NASDAQ:AMRI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, profitability and dividends.

Insider and Institutional Ownership

22.0% of OptiNose shares are held by institutional investors. Comparatively, 72.1% of Albany Molecular Research shares are held by institutional investors. 14.5% of Albany Molecular Research shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


This table compares OptiNose and Albany Molecular Research’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OptiNose N/A N/A N/A
Albany Molecular Research -5.93% -13.39% -3.42%

Earnings and Valuation

This table compares OptiNose and Albany Molecular Research’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
OptiNose N/A N/A N/A N/A N/A
Albany Molecular Research N/A N/A N/A ($1.43) -15.20

Analyst Ratings

This is a summary of recent recommendations and price targets for OptiNose and Albany Molecular Research, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OptiNose 0 0 4 0 3.00
Albany Molecular Research 0 4 0 0 2.00

OptiNose presently has a consensus target price of $29.25, indicating a potential upside of 66.29%. Albany Molecular Research has a consensus target price of $18.00, indicating a potential downside of 17.20%. Given OptiNose’s stronger consensus rating and higher possible upside, analysts clearly believe OptiNose is more favorable than Albany Molecular Research.


OptiNose beats Albany Molecular Research on 6 of the 8 factors compared between the two stocks.

About OptiNose

OptiNose, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other. The Company’s lead product, XHANCE (fluticasone propionate) nasal spray, utilizes breath powered exhalation delivery system (EDS), to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation.

About Albany Molecular Research

Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply